191 related articles for article (PubMed ID: 25662218)
1. FUBP1: a new protagonist in splicing regulation of the DMD gene.
Miro J; Laaref AM; Rofidal V; Lagrafeuille R; Hem S; Thorel D; Méchin D; Mamchaoui K; Mouly V; Claustres M; Tuffery-Giraud S
Nucleic Acids Res; 2015 Feb; 43(4):2378-89. PubMed ID: 25662218
[TBL] [Abstract][Full Text] [Related]
2. An exon skipping-associated nonsense mutation in the dystrophin gene uncovers a complex interplay between multiple antagonistic splicing elements.
Disset A; Bourgeois CF; Benmalek N; Claustres M; Stevenin J; Tuffery-Giraud S
Hum Mol Genet; 2006 Mar; 15(6):999-1013. PubMed ID: 16461336
[TBL] [Abstract][Full Text] [Related]
3. Skipping of an exon with a nonsense mutation in the DMD gene is induced by the conversion of a splicing enhancer to a splicing silencer.
Zhu Y; Deng H; Chen X; Li H; Yang C; Li S; Pan X; Tian S; Feng S; Tan X; Matsuo M; Zhang Z
Hum Genet; 2019 Jul; 138(7):771-785. PubMed ID: 31168774
[TBL] [Abstract][Full Text] [Related]
4. Identification of Splicing Factors Involved in DMD Exon Skipping Events Using an In Vitro RNA Binding Assay.
Miro J; Bourgeois CF; Claustres M; Koenig M; Tuffery-Giraud S
Methods Mol Biol; 2018; 1687():157-169. PubMed ID: 29067662
[TBL] [Abstract][Full Text] [Related]
5. Interaction of hnRNPA1/A2 and DAZAP1 with an Alu-derived intronic splicing enhancer regulates ATM aberrant splicing.
Pastor T; Pagani F
PLoS One; 2011; 6(8):e23349. PubMed ID: 21858080
[TBL] [Abstract][Full Text] [Related]
6. Bioinformatic and functional optimization of antisense phosphorodiamidate morpholino oligomers (PMOs) for therapeutic modulation of RNA splicing in muscle.
Popplewell LJ; Graham IR; Malerba A; Dickson G
Methods Mol Biol; 2011; 709():153-78. PubMed ID: 21194027
[TBL] [Abstract][Full Text] [Related]
7. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays.
Graham IR; Hill VJ; Manoharan M; Inamati GB; Dickson G
J Gene Med; 2004 Oct; 6(10):1149-58. PubMed ID: 15386737
[TBL] [Abstract][Full Text] [Related]
8. Disruption of the splicing enhancer sequence within exon 27 of the dystrophin gene by a nonsense mutation induces partial skipping of the exon and is responsible for Becker muscular dystrophy.
Shiga N; Takeshima Y; Sakamoto H; Inoue K; Yokota Y; Yokoyama M; Matsuo M
J Clin Invest; 1997 Nov; 100(9):2204-10. PubMed ID: 9410897
[TBL] [Abstract][Full Text] [Related]
9. Interplay between exonic splicing enhancers, mRNA processing, and mRNA surveillance in the dystrophic Mdx mouse.
Buvoli M; Buvoli A; Leinwand LA
PLoS One; 2007 May; 2(5):e427. PubMed ID: 17487273
[TBL] [Abstract][Full Text] [Related]
10. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy.
Gurvich OL; Tuohy TM; Howard MT; Finkel RS; Medne L; Anderson CB; Weiss RB; Wilton SD; Flanigan KM
Ann Neurol; 2008 Jan; 63(1):81-9. PubMed ID: 18059005
[TBL] [Abstract][Full Text] [Related]
11. Deletion of Dystrophin In-Frame Exon 5 Leads to a Severe Phenotype: Guidance for Exon Skipping Strategies.
Toh ZY; Thandar Aung-Htut M; Pinniger G; Adams AM; Krishnaswarmy S; Wong BL; Fletcher S; Wilton SD
PLoS One; 2016; 11(1):e0145620. PubMed ID: 26745801
[TBL] [Abstract][Full Text] [Related]
12. Splicing analysis disclosed a determinant single nucleotide for exon skipping caused by a novel intraexonic four-nucleotide deletion in the dystrophin gene.
Tran VK; Takeshima Y; Zhang Z; Yagi M; Nishiyama A; Habara Y; Matsuo M
J Med Genet; 2006 Dec; 43(12):924-30. PubMed ID: 16738009
[TBL] [Abstract][Full Text] [Related]
13. When a mid-intronic variation of DMD gene creates an ESE site.
Trabelsi M; Beugnet C; Deburgrave N; Commere V; Orhant L; Leturcq F; Chelly J
Neuromuscul Disord; 2014 Dec; 24(12):1111-7. PubMed ID: 25193336
[TBL] [Abstract][Full Text] [Related]
14. The splicing factor FUBP1 is required for the efficient splicing of oncogene MDM2 pre-mRNA.
Jacob AG; Singh RK; Mohammad F; Bebee TW; Chandler DS
J Biol Chem; 2014 Jun; 289(25):17350-64. PubMed ID: 24798327
[TBL] [Abstract][Full Text] [Related]
15. First Identification of RNA-Binding Proteins That Regulate Alternative Exons in the Dystrophin Gene.
Miro J; Bougé AL; Murauer E; Beyne E; Da Cunha D; Claustres M; Koenig M; Tuffery-Giraud S
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33096920
[TBL] [Abstract][Full Text] [Related]
16. Contributions of Japanese patients to development of antisense therapy for DMD.
Matsuo M; Takeshima Y; Nishio H
Brain Dev; 2016 Jan; 38(1):4-9. PubMed ID: 26094594
[TBL] [Abstract][Full Text] [Related]
17. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy.
Béroud C; Tuffery-Giraud S; Matsuo M; Hamroun D; Humbertclaude V; Monnier N; Moizard MP; Voelckel MA; Calemard LM; Boisseau P; Blayau M; Philippe C; Cossée M; Pagès M; Rivier F; Danos O; Garcia L; Claustres M
Hum Mutat; 2007 Feb; 28(2):196-202. PubMed ID: 17041910
[TBL] [Abstract][Full Text] [Related]
18. In vitro splicing analysis showed that availability of a cryptic splice site is not a determinant for alternative splicing patterns caused by +1G-->A mutations in introns of the dystrophin gene.
Habara Y; Takeshima Y; Awano H; Okizuka Y; Zhang Z; Saiki K; Yagi M; Matsuo M
J Med Genet; 2009 Aug; 46(8):542-7. PubMed ID: 19001018
[TBL] [Abstract][Full Text] [Related]
19. Optimizing antisense oligonucleotides using phosphorodiamidate morpholino oligomers.
Popplewell LJ; Malerba A; Dickson G
Methods Mol Biol; 2012; 867():143-67. PubMed ID: 22454060
[TBL] [Abstract][Full Text] [Related]
20. A G-to-T transversion at the splice acceptor site of dystrophin exon 14 shows multiple splicing outcomes that are not exemplified by transition mutations.
Ota M; Takeshima Y; Nishida A; Awano H; Lee T; Yagi M; Matsuo M
Genet Test Mol Biomarkers; 2012 Jan; 16(1):3-8. PubMed ID: 21854195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
